Breakthrough status for Padcev in combination with Keytruda

Padcev in combination with Keytruda has been granted Breakthrough Therapy status by the FDA for the treatment of patients in first-line advanced bladder cancer.

The designation was granted based on results from the dose-escalation cohort and expansion cohort A of the phase 1b/2 trial EV-103, evaluating patients with locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy treated in the first-line setting with Padcev (enfortumab vedotin-ejfv) in combination with Merck’s Keytruda (pembrolizumab).

EV-103 is an ongoing, multi-cohort, open-label, multicenter phase 1b/2 trial of Padcev alone or in combination, evaluating safety, tolerability and efficacy in muscle invasive, locally advanced and first- and second-line metastatic urothelial cancer.

“This is an important step in our investigation of Padcev in combination with pembrolizumab as a first-line therapy for patients with advanced urothelial cancer who are unable to receive cisplatin-based chemotherapy,” said Roger Dansey, Chief Medical Officer of Seattle Genetics.

“Based on encouraging early clinical activity, we recently initiated a phase 3 trial of this platinum-free combination and look forward to potentially addressing an unmet need for patients.”

Andrew Krivoshik, Senior Vice President and Oncology Therapeutic Area Head at Astellas, added: “The FDA’s Breakthrough Therapy designation reflects the encouraging preliminary evidence for the combination of Padcev and pembrolizumab in previously untreated advanced urothelial cancer to benefit patients who are in need of effective treatment options.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

FDA approves Roche’s Phesgo for HER2-positive breast cancer

The FDA has approved Phesgo, the fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous...

Carmine Therapeutics & Takeda to develop novel on-viral gene therapies

Carmine Therapeutics has signed a research collaboration agreement with Takeda to discover, develop and commercialise transformative non-viral gene therapies for two rare disease targets...

Catalent to fill-finish manufacture Moderna’s COVID-19 vaccine canidate

Moderna and Catalent have entered into a collaboration for large-scale, commercial fill-finish manufacturing of the former’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at the latter’s...

Enrolment opens for 4D Pharma’s phase II study of live biotherapeutic in COVID-19

4D Pharma, the listed Leeds-based pharma company developing Live Biotherapeutics, has announced that its Phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients...

Pharma industry invests £381m in UK R&D activities

The pharmaceutical industry has invested £381.2 million on R&D activities in the UK during 2019, up from £377.3 million in 2018, according to new...

Related news

CDMOs team up to simplify processes, optimise time-to-market

CDMOs Vetter and Rentschler Biopharma are collaborating to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain. With drug development...

FDA approves Roche’s Phesgo for HER2-positive breast cancer

The FDA has approved Phesgo, the fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous...

Carmine Therapeutics & Takeda to develop novel on-viral gene therapies

Carmine Therapeutics has signed a research collaboration agreement with Takeda to discover, develop and commercialise transformative non-viral gene therapies for two rare disease targets...

Catalent to fill-finish manufacture Moderna’s COVID-19 vaccine canidate

Moderna and Catalent have entered into a collaboration for large-scale, commercial fill-finish manufacturing of the former’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at the latter’s...